JP2024532677A5 - - Google Patents

Info

Publication number
JP2024532677A5
JP2024532677A5 JP2024505333A JP2024505333A JP2024532677A5 JP 2024532677 A5 JP2024532677 A5 JP 2024532677A5 JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024532677 A5 JP2024532677 A5 JP 2024532677A5
Authority
JP
Japan
Prior art keywords
moiety
oligo
auristatin
cancer
berotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532677A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2022/050782 external-priority patent/WO2023007481A1/en
Publication of JP2024532677A publication Critical patent/JP2024532677A/ja
Publication of JP2024532677A5 publication Critical patent/JP2024532677A5/ja
Pending legal-status Critical Current

Links

JP2024505333A 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用 Pending JP2024532677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL285208 2021-07-28
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532677A JP2024532677A (ja) 2024-09-10
JP2024532677A5 true JP2024532677A5 (cg-RX-API-DMAC10.html) 2025-07-23

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505333A Pending JP2024532677A (ja) 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用

Country Status (7)

Country Link
EP (1) EP4377292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532677A (cg-RX-API-DMAC10.html)
CN (1) CN117999254A (cg-RX-API-DMAC10.html)
AU (1) AU2022318483A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226393A1 (cg-RX-API-DMAC10.html)
IL (1) IL310354A (cg-RX-API-DMAC10.html)
WO (1) WO2023007481A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531620A (ja) * 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
KR102710962B1 (ko) * 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
AU2019365238A1 (en) * 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113613679A (zh) * 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法

Similar Documents

Publication Publication Date Title
JP7403507B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
CN113827736B (zh) 一种带有高稳定性亲水连接单元的喜树碱类药物及其偶联物
JP2022530524A5 (cg-RX-API-DMAC10.html)
JP2025106317A (ja) 生物活性分子コンジュゲート、その調製法及び使用
JP6871858B2 (ja) 抗体薬物コンジュゲート
BR112021004656A2 (pt) conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
WO2024235136A9 (zh) 杂环类化合物及其制备方法和用途
JPH02191300A (ja) 抗体―薬物抱合体
WO2024235134A9 (zh) 具有靶向作用的偶联物及其制备方法和用途
WO2024235130A1 (zh) 多环化合物及其制备方法和用途
WO2024235133A9 (zh) 多环类药物偶联物及其制备方法和用途
WO2024235135A1 (zh) 大环化合物及其制备方法和用途
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
JP2025514436A (ja) 親水性糖構造を含むリガンド薬物複合体
JP7753523B2 (ja) Sn38を含む抗体-薬物コンジュゲートの中間体及びその調製方法
CN118767158A (zh) 一种抗体-药物偶联物及其制备方法和用途
AU2024208501A1 (en) Ligand-drug conjugates
JP2025507707A (ja) 新規の抗体薬剤コンジュゲート
WO2025232688A1 (zh) 并环类药物偶联物及其制备方法和用途
JP2025513664A5 (cg-RX-API-DMAC10.html)
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
JP2025532285A (ja) 高安定性親水性リンカーユニットを有するアウリスタチン系薬物及びその複合体
HK40104908A (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof